|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW, UK2 Department of Biochemistry, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK
This study's rationale was that the expression and activity of aspartate transporters in hypertrophied hearts might be different from normal hearts, which could affect the use of aspartate in myocardial protection of hypertrophied hearts. mRNA expression of system Xag transporters in hearts from normal (Wistar Kyoto) and hypertrophied (spontaneously hypertensive rat) rats was investigated by RT-PCR. EAAT3 protein expression in isolated cells and vesicles from normal and hypertrophied hearts was investigated by Western blotting. The same vesicles were also used to measure aspartate uptake. The effects of 0.5 mmol l1 aspartate supplementation on cardiac performance during ischaemiareperfusion were investigated in isolated and perfused hearts. Both normal and hypertrophied hearts expressed EAAT1 and EAAT3 mRNA. EAAT3 protein expression was significantly greater in cells and vesicles from hypertrophied hearts compared to normal hearts. The velocity (Vmax) of aspartate uptake was faster at 24.4 ± 2.2 pmol mg1 s1 in vesicles from hypertrophied hearts compared to 8.2 ± 0.8 pmol mg1 s1 (P < 0.001, t test, n= 6, means ±S.E.M.) in normal heart vesicles. The affinity (Km) was similar for both preparations. When recoveries were matched, 0.5 mmol l1 aspartate addition reduced reperfusion injury and increased functional recovery of hypertrophied hearts but not normal hearts. This was associated with a greater preservation of ATP, glutamate and glutamine and less lactate production during ischaemia in aspartate-treated hypertrophied hearts compared to all other experimental groups. These results suggest that increased aspartate transporter expression and activity in hypertrophy helps facilitate aspartate entry into hypertrophied cardiomyocytes, which in turn leads to improved myocardial protection.
(Received 5 January 2004;
accepted after revision 3 February 2004;
first published online 6 February 2004)
Corresponding author N. King: Bristol Heart Institute, Bristol Royal Infirmary, Bristol BS2 8HW, UK. Email: n.king{at}bris.ac.uk
This article has been cited by other articles:
![]() |
A. Vranyac-Tramoundanas, J. C. Harrison, A. N. Clarkson, M. Kapoor, I. C. Winburn, D. S. Kerr, and I. A. Sammut Domoic Acid Impairment of Cardiac Energetics Toxicol. Sci., October 1, 2008; 105(2): 395 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chung Oxygen reperfusion is limited in the postischemic hypertrophic myocardium Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2075 - H2084. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |